LOW-DOSES OF SUPEROXIDE-DISMUTASE AND A STABLE PROSTACYCLIN ANALOG PROTECT IN MYOCARDIAL-ISCHEMIA AND REPERFUSION

被引:16
作者
MA, XL
JOHNSON, G
LEFER, AM
机构
[1] THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PHYSIOL,1020 LOCUST ST,PHILADELPHIA,PA 19107
[2] THOMAS JEFFERSON UNIV,ISCHEMIA SHOCK RES INST,PHILADELPHIA,PA 19107
关键词
D O I
10.1016/0735-1097(92)90073-V
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effects of low dose human superoxide dismutase and low dose taprostene, a stable analogue of prostacyclin, were investigated separately and together in a model of myocardial ischemia (1.5 h) with reperfusion (4.5 h) in open chest, anesthetized cats. Taprostene (60 ng/kg per min), human superoxide dismutase (0.25 mg/kg per h), both agents together, or their vehicle, were infused intravenously in cats starting 0.5 h after occlusion of the left anterior descending coronary artery. Neither low dose taprostene nor low dose human superoxide dismutase exerted any endothelial or myocardial protection in this model. However, the two agents together showed a significant endothelial and myocardial protection in cats with myocardial ischemia and reperfusion. Compared with cats that were untreated or received only taprostene or human superoxide dismutase, cats receiving both agents exhibited a lower plasma creatine kinase activity at every time point observed after reperfusion, a reduced area of cardiac necrosis (7 +/- 2% vs. 21 +/- 5% area at risk, p < 0.001), lower myeloperoxidase activity in the ischemic region (p < 0.01) and a significant preservation of vasorelaxant responses of left anterior descending coronary rings to endothelium-dependent vasodilators, acetylcholine (p < 0.001) and A-23187 (p < 0.001). Taprostene appears to act additively with human superoxide dismutase to inhibit neutrophil adherence and activation and to inactivate superoxide radicals, and thus reduce cellular injury 4.5 h after reperfusion of the ischemic heart. Use of this agent may allow low doses of superoxide dismutase to be used more effectively in early myocardial ischemia.
引用
收藏
页码:197 / 204
页数:8
相关论文
共 34 条
[1]   REDUCTION IN EXPERIMENTAL INFARCT SIZE BY RECOMBINANT HUMAN SUPEROXIDE-DISMUTASE - INSIGHTS INTO THE PATHOPHYSIOLOGY OF REPERFUSION INJURY [J].
AMBROSIO, G ;
BECKER, LC ;
HUTCHINS, GM ;
WEISMAN, HF ;
WEISFELDT, ML .
CIRCULATION, 1986, 74 (06) :1424-1433
[2]   CARDIOPROTECTIVE ACTIONS OF HUMAN SUPEROXIDE-DISMUTASE IN 2 REPERFUSION MODELS OF MYOCARDIAL ISCHEMIA IN THE RAT [J].
AOKI, N ;
BITTERMAN, H ;
BREZINSKI, ME ;
LEFER, AM .
BRITISH JOURNAL OF PHARMACOLOGY, 1988, 95 (03) :735-740
[3]   MEASUREMENT OF CUTANEOUS INFLAMMATION - ESTIMATION OF NEUTROPHIL CONTENT WITH AN ENZYME MARKER [J].
BRADLEY, PP ;
PRIEBAT, DA ;
CHRISTENSEN, RD ;
ROTHSTEIN, G .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1982, 78 (03) :206-209
[4]   MYOCARDIAL REPERFUSION - A DOUBLE-EDGED SWORD [J].
BRAUNWALD, E ;
KLONER, RA .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 76 (05) :1713-1719
[5]  
BULKLEY GB, 1989, SPLANCHNIC ISCHEMIA, P183
[6]   CAN SUPEROXIDE-DISMUTASE ALTER MYOCARDIAL INFARCT SIZE [J].
ENGLER, R ;
GILPIN, E .
CIRCULATION, 1989, 79 (05) :1137-1142
[7]  
GORNALL AG, 1949, J BIOL CHEM, V177, P751
[8]   ENDOTHELIUM AND MYOCARDIAL PROTECTING ACTIONS OF TAPROSTENE, A STABLE PROSTACYCLIN ANALOG, AFTER ACUTE MYOCARDIAL-ISCHEMIA AND REPERFUSION IN CATS [J].
JOHNSON, G ;
FURLAN, LE ;
AOKI, N ;
LEFER, AM .
CIRCULATION RESEARCH, 1990, 66 (05) :1362-1370
[9]  
JOHNSON G, 1990, J PHARMACOL EXP THER, V252, P35
[10]   SYNERGISM BETWEEN SUPEROXIDE-DISMUTASE AND SODIUM-NITRITE IN CARDIOPROTECTION FOLLOWING ISCHEMIA AND REPERFUSION [J].
JOHNSON, G ;
TSAO, P ;
LEFER, AM .
AMERICAN HEART JOURNAL, 1990, 119 (03) :530-537